Amir Dan Rubin - 07 Oct 2022 Form 4 Insider Report for 1Life Healthcare Inc

Signature
/s/ Ivy Tseng, Attorney-in-Fact for Amir Dan Rubin
Issuer symbol
N/A
Transactions as of
07 Oct 2022
Net transactions value
-$16,021,012
Form type
4
Filing time
12 Oct 2022, 18:50:15 UTC
Previous filing
06 Oct 2022
Next filing
05 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONEM Common Stock Options Exercise $4,526,817 +1,128,882 +1132% $4.01 1,228,630 07 Oct 2022 Direct
transaction ONEM Common Stock Options Exercise $2,800,237 +242,235 +20% $11.56 1,470,865 07 Oct 2022 Direct
transaction ONEM Common Stock Sale $23,348,066 -1,371,117 -93% $17.03 99,748 07 Oct 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONEM Stock Options (Right to buy) Options Exercise $0 -1,128,882 -100% $0.000000* 0 07 Oct 2022 Common Stock 1,128,882 $4.01 Direct F3
transaction ONEM Stock Option (Right to Buy) Options Exercise $0 -242,235 -10% $0.000000 2,064,765 07 Oct 2022 Common Stock 242,235 $11.56 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and were conducted by the reporting person for tax and estate planning purposes. The reporting person has adopted Rule 10b5-1 plans in the past and has adopted this Rule 10b5-1 plan in the ordinary course. The trading plans and their parameters do not reflect the reporting person's views on the closing of the pending, previously announced, merger or the prospects of the Company's business after the closing.
F2 This transaction was executed in multiple trades at prices ranging from $16.95 to $17.085. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The shares subject to the option vested as follows: 20% of the shares subject to the option vested on the first anniversary of the vesting commencement date; and 1/60th of the shares subject to the option vested monthly thereafter over the following four years, subject to the reporting person's continuous service as of each such date.
F4 The shares subject to the option vest as follows: 63% of the shares subject to the option vest ratably on a monthly basis from the vesting commencement date through August 2023; 25% of the shares subject to the option vest ratably on a monthly basis from September 2023 to August 2024; and the remaining 12% of the shares subject to the option vest ratably on a monthly basis from September 2024 to August 2025, subject to the reporting person's continuous service as of each such date.